Fraser Dove International

👇 𝐓𝐡𝐞𝐬𝐞 𝐀𝐫𝐞 𝐘𝐨𝐮𝐫 𝐓𝐨𝐩 𝟓 𝐍𝐞𝐰𝐬 𝐒𝐭𝐨𝐫𝐢𝐞𝐬 𝐀𝐫𝐨𝐮𝐧𝐝 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐁𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐬 𝐘𝐨𝐮 𝐍𝐞𝐞𝐝 𝐭𝐨 𝐑𝐞𝐚𝐝 𝐓𝐡𝐢𝐬 𝐖𝐞𝐞𝐤 👇 1️⃣ A new regulatory T-cell therapy dramatically reduces immune overreaction to gluten in mouse models of coeliac disease. Published in Science Translational Medicine, the study shows engineered T cells suppress gluten-sensitive effector cells. This could lead to human trials and offer an alternative to strict gluten-free diets. 📰 https://lnkd.in/gHvCZ48v 2️⃣ Verve Therapeutics got FDA clearance to expand its Heart-2 trial in the US, testing VERVE-102 — a gene-editing therapy that permanently lowers LDL cholesterol by disabling the PCSK9 gene in liver cells. Aiming to replace injectable PCSK9 drugs, it targets inherited high cholesterol and early-onset heart disease. 📰 https://lnkd.in/emMr9X2v 3️⃣ A study confirms the high accuracy of plasma p-tau217 in detecting beta-amyloid (Aβ), even in people with cerebrovascular disease — common in Asian populations. This biomarker could enhance early Alzheimer’s detection and care in high-risk regions. 📰 https://lnkd.in/ezaY3svy 4️⃣ Axsome Therapeutics reports positive Phase 3 results for Sunosi (solriamfetol) in adult ADHD. Originally approved for narcolepsy and sleep apnea, Sunosi showed strong symptom reduction and a good safety profile, positioning it as a non-stimulant treatment option. 📰 https://lnkd.in/g5p5SX2f 5️⃣ GSK’s Blujepa (gepotidacin) won FDA approval as the first new oral antibiotic class for UTIs in nearly 30 years. Effective against common pathogens like E. coli, it addresses rising antibiotic resistance and is a key step in GSK’s infectious disease strategy. 📰 https://lnkd.in/eruv3dNY #ResearchBreakthroughs | #LifeSciences | #NewsRoundUp

“𝐖𝐢𝐥𝐥 𝐰𝐚𝐬 𝐯𝐞𝐫𝐲 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐢𝐯𝐞 𝐭𝐨 𝐦𝐞, 𝐚𝐧𝐝 𝐡𝐞 𝐚𝐥𝐰𝐚𝐲𝐬 𝐚𝐜𝐭𝐞𝐝 𝐢𝐧 𝐨𝐫𝐝𝐞𝐫 𝐭𝐨 𝐥𝐨𝐨𝐤 𝐟𝐨𝐫 𝐚 𝐰𝐢𝐧 𝐰𝐢𝐧 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐛𝐞𝐭𝐰𝐞𝐞𝐧 𝐦𝐞 𝐚𝐧𝐝 𝐄𝐮𝐫𝐨𝐀𝐏𝐈”. ✅ Managing both sides flawlessly ✅ Our Principal Consultant, Will Burnell, finding the best possible outcome for both candidate and client 😊 #ExecutiveSearch | #LifeSciences | #FraserDove | #Testimonial

🌟 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐀𝐫𝐞𝐧’𝐭 𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐨𝐧 🌟 Did you manage to tune in to our latest Lift Up Live Broadcast? In this broadcast, 𝐂𝐨𝐧𝐧𝐞𝐜𝐭𝐢𝐧𝐠 𝐏𝐞𝐞𝐫𝐬, 𝐂𝐫𝐞𝐚𝐭𝐢𝐧𝐠 𝐏𝐨𝐰𝐞𝐫 𝐇𝐨𝐮𝐬𝐞𝐬, we explored the power of community and what it can do to transform your professional and personal life. To do so, we were privileged to welcome our panel of experts including Kattayoun (Kathy) Kordy, M.D. (Chief Growth Officer of Under the Sisterhood), Miriam Kenrick (Co-Founder ofWomen in Pharma (WiP)), and Gina Ford (Executive Director of Women In Bio - Engage. Educate. Empower.). Here, Miriam discusses her initial instincts when it came to starting her community. She explains that her biggest worry was that her community would not be unique enough in comparison to existing ones. However, she came to the realisation that these communities are not in competition and are all working towards a common goal. 👇 𝐈𝐟 𝐲𝐨𝐮 𝐦𝐢𝐬𝐬𝐞𝐝 𝐭𝐡𝐞 𝐛𝐫𝐨𝐚𝐝𝐜𝐚𝐬𝐭 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐭𝐢𝐦𝐞 𝐫𝐨𝐮𝐧𝐝, 𝐲𝐨𝐮 𝐜𝐚𝐧 𝐬𝐭𝐢𝐥𝐥 𝐰𝐚𝐭𝐜𝐡 𝐢𝐭 𝐢𝐧 𝐟𝐮𝐥𝐥 𝐛𝐞𝐥𝐨𝐰 👇 https://lnkd.in/e-HX9BAn #Allies #Community #LiftUp

1️⃣ 𝐀𝐫𝐞 𝐲𝐨𝐮 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞𝐝 𝐢𝐧 𝐝𝐫𝐢𝐯𝐢𝐧𝐠 𝐏&𝐋 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐰𝐢𝐭𝐡𝐢𝐧 𝐭𝐡𝐞 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲? 2️⃣ 𝐃𝐨 𝐲𝐨𝐮 𝐡𝐚𝐯𝐞 𝐚 𝐬𝐭𝐫𝐨𝐧𝐠 𝐛𝐚𝐜𝐤𝐠𝐫𝐨𝐮𝐧𝐝 𝐢𝐧 𝐦𝐚𝐧𝐚𝐠𝐢𝐧𝐠 𝐩𝐫𝐨𝐝𝐮𝐜𝐭 𝐥𝐚𝐮𝐧𝐜𝐡𝐞𝐬 𝐟𝐨𝐫 𝐠𝐞𝐧𝐞𝐫𝐢𝐜 𝐢𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞𝐬? 3️⃣ 𝐂𝐚𝐧 𝐲𝐨𝐮 𝐥𝐞𝐚𝐝 𝐚 𝐭𝐞𝐚𝐦 𝐭𝐨 𝐦𝐞𝐞𝐭 𝐚𝐦𝐛𝐢𝐭𝐢𝐨𝐮𝐬 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐠𝐫𝐨𝐰𝐭𝐡 𝐭𝐚𝐫𝐠𝐞𝐭𝐬? ✅ A resounding, yes? This role could be for you ✅ Fraser Dove International is partnering exclusively with a leading generic pharmaceutical organisation. As 𝐃𝐢𝐫𝐞𝐜𝐭𝐨𝐫 𝐨𝐟 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐌𝐚𝐫𝐤𝐞𝐭𝐢𝐧𝐠, some of your responsibilities will include managing profit and loss (P&L) responsibilities for the injectable product portfolio, including pricing, forecasting, budgeting, and bid processes. You will also be developing and executing marketing plans for the injectable portfolio, with a focus on individual molecule strategies and new product launches. ✅ Resonating? This could be your next challenge ✅ https://lnkd.in/eQtYPyU2 Alternatively, contact Olivia Mitchener for more information on this and similar opportunities with life science organisations in America, Asia, and Europe. #DirectorofProductMarketing #LifeSciences #FraserDove #RoleOfTheWeek

𝐋𝐢𝐟𝐭 𝐔𝐩: 𝐀𝐥𝐥𝐲𝐬𝐡𝐢𝐩 𝐢𝐧 𝐀𝐜𝐭𝐢𝐨𝐧, 𝐁𝐮𝐢𝐥𝐝𝐢𝐧𝐠 𝐋𝐞𝐚𝐝𝐞𝐫𝐬 & 𝐅𝐨𝐥𝐥𝐨𝐰𝐞𝐫𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 No matter your career stage or industry, allyship and advocacy are powerful drivers of success. But how can male leaders actively foster growth, inclusion, and followership to empower women in their careers? Join us LIVE on LinkedIn Thursday, 17th April at 16:15 GMT for a game-changing conversation! This time, we’re flipping the script and handing the mic to top male leaders in life sciences to discuss how they can drive real change. Hosted by our CCO & LinkedIn Top Voice, Andrew MacAskill, we’ll dive into what it takes to be an impactful ally, one who champions, elevates, and empowers female careers for the long run. 𝐎𝐮𝐫 𝐏𝐚𝐧𝐞𝐥𝐥𝐢𝐬𝐭𝐬: 🔊 Alexander Seyf, Chief Executive Officer at Autolomous 🔊 Juan Camilo Arjona Ferreira, Head of R&D and Chief Medical Officer at Organon 🔊 Jimmy V., Chief Executive Officer at Viralgen 𝐖𝐡𝐚𝐭 𝐘𝐨𝐮'𝐥𝐥 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫:  🚀 Breaking Stereotypes – What myths hold male leaders back from being great allies? 💡 Followership 101 – How can male leaders earn trust, respect, and influence among women? ⚡ Mentorship or Misstep? – The key Do’s & Don’ts when supporting female talent. 🎯 The Power of One – How a single great ally can shape the future of a woman’s career. Whether you're a Board Member, Professional, Educator, Student, or simply seeking direction, this session will aim to connect, inspire and empower. 🔔 𝐋𝐢𝐯𝐞 𝐐&𝐀: As always you can engage directly with our panellists and get your questions answered. Don't miss this opportunity to be a part of our community to listen, learn and get inspired by our industry guests. Register now 👇

🂡 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐡𝐨𝐰 𝐫𝐞𝐭𝐞𝐧𝐭𝐢𝐨𝐧 𝐢𝐬 𝐲𝐨𝐮𝐫 𝐚𝐜𝐞 𝐜𝐚𝐫𝐝 𝐢𝐧 𝐮𝐧𝐥𝐨𝐜𝐤𝐢𝐧𝐠 𝐛𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐠𝐫𝐨𝐰𝐭𝐡 𝐢𝐧 𝟐𝟎𝟐𝟒 𝐰𝐢𝐭𝐡 𝐨𝐮𝐫 𝐞𝐆𝐮𝐢𝐝𝐞 🂡 Actionable retainment tips for life science execs. Grab your 𝐅𝐑𝐄𝐄 copy in the link in the comments 👇 https://bit.ly/4aqwSci

1️⃣ 𝐇𝐚𝐯𝐞 𝐲𝐨𝐮 𝐠𝐨𝐭 𝐐𝐮𝐚𝐥𝐢𝐭𝐲 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐢𝐧 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥/𝐛𝐢𝐨𝐭𝐞𝐜𝐡? 2️⃣ 𝐃𝐨 𝐲𝐨𝐮 𝐡𝐚𝐯𝐞 𝐞𝐱𝐭𝐞𝐧𝐬𝐢𝐯𝐞 𝐥𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐦𝐚𝐧𝐚𝐠𝐢𝐧𝐠 𝐥𝐚𝐲𝐞𝐫𝐞𝐝 𝐭𝐞𝐚𝐦𝐬 𝐨𝐟 𝟐𝟓+? 3️⃣ 𝐇𝐚𝐯𝐞 𝐲𝐨𝐮 𝐠𝐨𝐭 𝐬𝐭𝐫𝐨𝐧𝐠 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐰𝐢𝐭𝐡 𝐅𝐃𝐀 𝐚𝐧𝐝 𝐄𝐌𝐀? ✅ Tick, tick and tick, this role may be the perfect fit! ✅ Fraser Dove International is partnering exclusively with a leading pharmaceutical organisation, operating globally. As 𝐒𝐢𝐭𝐞 𝐇𝐞𝐚𝐝 𝐨𝐟 𝐐𝐮𝐚𝐥𝐢𝐭𝐲, some of your responsibilities will include ensuring the site Quality Management System is efficient and aligned with company standards, local and global regulations. You will also manage the Quality Unit (Quality Assurance, Quality Control) to ensure that materials and products manufactured, controlled, stored and shipped to meet the appropriate Quality Standards and are in compliance with current Good Manufacturing Practices (cGMPs). 𝐅𝐞𝐞𝐥 𝐫𝐢𝐠𝐡𝐭? 𝐀𝐩𝐩𝐥𝐲 𝐭𝐨𝐝𝐚𝐲 𝐯𝐢𝐚 𝐭𝐡𝐞 𝐥𝐢𝐧𝐤 𝐛𝐞𝐥𝐨𝐰 👇 https://lnkd.in/ezWg6szN Alternatively, contact Peter Vedde for more information on this and similar opportunities with life science organisations in America, Asia, and Europe. #SiteHeadofQuality #LifeSciences #FraserDove #RoleOfTheWeek

“𝐕𝐞𝐫𝐲 𝐜𝐨𝐦𝐦𝐮𝐧𝐢𝐜𝐚𝐭𝐢𝐯𝐞, 𝐯𝐞𝐫𝐲 𝐡𝐞𝐥𝐩𝐟𝐮𝐥 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐩𝐫𝐨𝐜𝐞𝐬𝐬, 𝐦𝐞𝐞𝐭𝐢𝐧𝐠 𝐩𝐫𝐞𝐩, 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐭𝐲 𝐩𝐫𝐞𝐩. 𝐒𝐡𝐞 𝐝𝐢𝐝 𝐚 𝐟𝐚𝐧𝐭𝐚𝐬𝐭𝐢𝐜 𝐣𝐨𝐛 𝐨𝐟 𝐦𝐚𝐤𝐢𝐧𝐠 𝐬𝐮𝐫𝐞 𝐈 𝐡𝐚𝐝 𝐞𝐯𝐞𝐫𝐲𝐭𝐡𝐢𝐧𝐠 𝐈 𝐧𝐞𝐞𝐝𝐞𝐝 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐩𝐫𝐨𝐜𝐞𝐬𝐬”. ✅ With our candidates every step of the way ✅ Our Search Consultant, Charley Hobson, being a true ally to our candidates 😊 #ExecutiveSearch | #LifeSciences | #FraserDove | #Testimonial

🌟 𝐁𝐮𝐢𝐥𝐝 𝐓𝐫𝐮𝐬𝐭 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 𝐑𝐢𝐠𝐡𝐭 𝐏𝐞𝐨𝐩𝐥𝐞 🌟 Did you manage to tune in to our latest Lift Up Live Broadcast? In this broadcast, 𝐂𝐨𝐧𝐧𝐞𝐜𝐭𝐢𝐧𝐠 𝐏𝐞𝐞𝐫𝐬, 𝐂𝐫𝐞𝐚𝐭𝐢𝐧𝐠 𝐏𝐨𝐰𝐞𝐫 𝐇𝐨𝐮𝐬𝐞𝐬, we explored the power of community and what it can do to transform your professional and personal life. To do so, we were privileged to welcome our panel of experts including Kattayoun (Kathy) Kordy, M.D. (Chief Growth Officer of Under the Sisterhood), Miriam Kenrick (Co-Founder of Women in Pharma (WiP)), and Gina Ford (Executive Director of Women In Bio - Engage. Educate. Empower.). Here, Gina shares her background on how her career has progressed. She explains that the way she progressed was to keep in mind where she wanted to go next and who can help her get there. She highlights the importance of having a strong network and that trust is crucial in these relationships. 👇 𝐈𝐟 𝐲𝐨𝐮 𝐦𝐢𝐬𝐬𝐞𝐝 𝐭𝐡𝐞 𝐛𝐫𝐨𝐚𝐝𝐜𝐚𝐬𝐭 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐭𝐢𝐦𝐞 𝐫𝐨𝐮𝐧𝐝, 𝐲𝐨𝐮 𝐜𝐚𝐧 𝐬𝐭𝐢𝐥𝐥 𝐰𝐚𝐭𝐜𝐡 𝐢𝐭 𝐢𝐧 𝐟𝐮𝐥𝐥 𝐛𝐞𝐥𝐨𝐰 👇 https://lnkd.in/e-HX9BAn #Trust #Network #LiftUp

👇 𝐓𝐡𝐞𝐬𝐞 𝐀𝐫𝐞 𝐘𝐨𝐮𝐫 𝐓𝐨𝐩 𝟓 𝐍𝐞𝐰𝐬 𝐒𝐭𝐨𝐫𝐢𝐞𝐬 𝐀𝐫𝐨𝐮𝐧𝐝 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐀𝐜𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬 𝐘𝐨𝐮 𝐍𝐞e𝐝 𝐭𝐨 𝐑𝐞𝐚𝐝 𝐓𝐡𝐢𝐬 𝐖𝐞𝐞𝐤 👇 1️⃣ The US Food and Drug Administration (FDA) has approved scPharmaceuticals’ supplemental new drug application (sNDA) for Furoscix (furosemide), expanding its use to treat oedema in chronic kidney disease (CKD) patients, including those with nephrotic syndrome. The therapy will be available from April 2025. 📰 https://lnkd.in/ec6wA794 2️⃣ Indonesia’s National Agency of Drug and Food Control has approved Xpovio (selinexor) for three indications, expanding its use in treating multiple myeloma (MM) and relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). With this approval, Xpovio is now approved in 10 Asia-Pacific (APAC) nations, with further expansion plans in the ASEAN region. 📰 https://lnkd.in/eEJsh9sp 3️⃣ The FDA has approved ARS Pharmaceuticals’ Neffy 1mg, a needle-free epinephrine nasal spray for paediatric patients (ages 4+) weighing 15–30kg, to treat severe allergic reactions, including anaphylaxis. This approval follows clinical trials showing comparable effectiveness to traditional epinephrine injections. Neffy 1mg will be available in the US by May 2025. 📰 https://lnkd.in/ePNTZzBn 4️⃣ The FDA has granted Orphan Drug Designation (ODD) to Plus Therapeutics’ Rhenium (186Re) Obisbemeda, an injectable radiotherapy for leptomeningeal metastases (LM) in lung cancer patients. This designation, following the Phase I ReSPECT-LM trial, provides market exclusivity and regulatory incentives to encourage development. Phase II and additional Phase I trials are ongoing. 📰 https://lnkd.in/eKhxdENk 5️⃣ A federal court in Texas has ruled against compounding pharmacies, preventing them from continuing to manufacture copycat versions of Eli Lilly’s tirzepatide products (Mounjaro and Zepbound). This decision reinforces Lilly’s exclusive market rights and confirms that the FDA-approved versions are not in shortage. While small-scale state-licensed compounders must halt production immediately, federally licensed ones have until March 19, 2025. The ruling does not impact compounded versions of Novo Nordisk’s semaglutide (Ozempic, Wegovy), which are subject to a separate lawsuit. 📰 https://lnkd.in/gn_rhffs #RegulatoryActionsAndApprovals | #LifeSciences | #NewsRoundUp